Laith A.I.K. Al-Kaif

Dr. Laith A.I.K. Al-Kaif

orcid
0000-0003-3137-2790

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MAMohammed Ahmed Akkaif
Mohammed Ahmed Akkaif
ABAhmad Bitar
Ahmad Bitar
Laith A.I.K. Al-KaifLaith A.I.K. Al-Kaif
Laith A.I.K. Al-Kaif
NDNur Aizati Athirah Daud
Nur Aizati Athirah Daud
Abubakar Sha'abanAbubakar Sha'aban
Abubakar Sha'aban
BIBaharudin Ibrahim
Baharudin Ibrahim
The global evolution of the SARS-CoV-2 virus is known to all. The diagnosis of SARS-CoV-2 pneumonia is expected to worsen, and mortality will be higher when combined with myocardial injury (MI). The combination of novel coronavirus infections in patients with MI can cause confusion in diagnosis and assessment, with each condition exacerbating the other, and increasing the complexity and difficulty of treatment. It would be a formidable challenge for clinical practice to deal with this situation. Therefore, this review aims to gather literature on the progress in managing MI related to SARS-CoV-2 pneumonia. This article reviews the definition, pathogenesis, clinical evaluation, management, and treatment plan for MI related to SARS-CoV-2 pneumonia based on the most recent literature, diagnosis, and treatment trial reports. Many studies have shown that early diagnosis and implementation of targeted treatment measures according to the different stages of disease can reduce the mortality rate among patients with MI related to SARS-CoV-2 pneumonia. The reviewed studies show that multiple strategies have been adopted for the management of MI related to COVID-19. Clinicians should closely monitor SARS-CoV-2 pneumonia patients with MI, as their condition can rapidly deteriorate and progress to heart failure, acute myocardial infarction, and/or cardiogenic shock. In addition, appropriate measures need to be implemented in the diagnosis and treatment to provide reasonable care to the patient.

1 April 2025 in Medical Journal of Babylon
Verified
Journal Article
Open access
WAWael Rasheed Obaead Alfatlawi
Wael Rasheed Obaead Alfatlawi
Laith A.I.K. Al-KaifLaith A.I.K. Al-Kaif
Laith A.I.K. Al-Kaif
AMAmmar Eesa Mahdi
Ammar Eesa Mahdi
YAYounis A. K. Al-Khafaji
Younis A. K. Al-Khafaji
MAMohammad Abd-Kadhum Al-Saadi
Mohammad Abd-Kadhum Al-Saadi
MSMohammed Sameir Shaker
Mohammed Sameir Shaker
Background: Human cytomegalovirus (HCMV) is one of the important viruses involved in the progression of autoimmune diseases affecting the gastrointestinal system. Objectives: This study was conducted to evaluate the immune status of celiac disease (CD) with cytomegalovirus (CMV). Materials and Methods: This study included 68 subjects with suspected CD, which was collected during the period extent from January 2024 to March 2024. The immune status was evaluated using the enzyme-linked immunosorbent assay (ELISA) test to determine anti-Ttg A, anti-Ttg G, anti-gliadin IgA, and anti-gliadin IgG as well as anti-CMV IgM/IgG. Results: The results of the present study showed that 22 cases of CD were confirmed, with significantly higher percentages of positive results (18.2%, 68.2%) for patients compared to the control groups (2.2%, 13%) according to anti-gliadin A/G, respectively. Moreover, the level of anti-HCMV IgG antibodies in the serum samples of patients suffering from CD revealed significant differences of 3.39 ± 1.12 and 2.51 ± 0.835 between the patient and the control groups, respectively. Conclusion: It could be concluded that CMV infection may be involved in CD in terms of factors that stimulate or enhance autoimmunity or in the immunosuppressive state of the disease. Thus, CMV is a major contributor to the increased incidence of CD and likely worsens the prognosis of the disease.